ConLife Med Announces IPO Filing Following Breakthrough in PFO Closure Device Innovation

Aug 26, 2024 16:45 CST Updated 16:45

Conmind

Cardiovascular and Cerebrovascular Interventional Products R&D and Manufacturer

Source: Siyu MedTech; Editor: Qi Yuan

Reprint requirements: Can be reprinted 24 hours after the first publication, source must be credited.

On June 28, 2024, Siyu MedTech hosted theGlobal Medical Technology Conference(Global MedTech Conference 2024) Grandly Opens at the Exhibition Center Conference Center of Zhongguan Village National Independent Innovation Demonstration Zone.

The conference brought together relevant departments and bureaus of Beijing Municipality,More than 450 companies, over 60 medical institutions, more than 20 investment firms, and over 10 universities from across China, with a total of 600 participants attending., and jointly discuss important topics such as industry development trends, policy directions, technological innovations, and international cooperation.

At the opening ceremony,Person from Haidian District, BeijingDeputy District Chief Lin Hang of the People's Government, Fan Yubo, Dean of the School of Biological Science and Medical Engineering at Beihang University, and other leaders delivered speeches. Liu Qinghua, Deputy Director of the Beijing Center for Disease Control and Prevention and Director of the Pharmaceutical and Device Department of the Beijing Health Commission, Ma Limei, Deputy Director of the Beijing Medical and Health Science and Technology Development Center, and Cheng Wanhui, Director of the Third Department of Industrial Promotion at the Zhongguancun Science Park Management Committee, respectively gave reports introducing Beijing's biopharmaceutical industry and relevant policies from associated committees and offices.

At the conference,Co-founder of ConmindMr. Huang Hui(hereinafter referred to as "Mr. Huang") delivered a speech entitled"Device Innovation - From Clinical Needs to Engineering Implementation"The wonderful speech elaborated on the company's latest progress and innovative achievements in the research and development of cardiovascular and cerebrovascular interventional products, and shared profound insights and practical experience in medical device innovation.

# The Rise and Vision of CONMIND MEDICAL

Huang introduced the background and development history of CONMIND MEDICAL first.Conmind Medical Group, founded in 2020 and headquartered in Shenzhen, China, is a high-tech medical device company specializing in the research, development, production, and sales of cardiovascular and cerebrovascular interventional products. The company currently has more than 160 employees and has applied for over 200 patents worldwide.

Huang, the CEO, stated: "Conmind is committed to exploring innovative treatment solutions in the fields of cardiology, cerebrovascular, and peripheral vascular diseases, providing safe, effective, innovative, and reliable neurointerventional and cardiac interventional diagnostic and therapeutic devices for patients and medical professionals worldwide."

Conmind's products cover two major clusters: neurointervention and structural heart disease, and the entire series of products have independent intellectual property rights.The company owns a CNAS-accredited high-end laboratory and a Class 10,000 cleanroom workshop, with mature cardiovascular product process technology and R&D capabilities. It is equipped with fully functional medical device production equipment and has an experienced R&D team and sales staff. General Manager Huang emphasized: "Our goal is to become a globally leading and trusted medical service provider for doctors and patients."

# Clinical Needs and Innovation Challenges

Huang, in his speech, pointed out,Currently, there is an abnormal channel in the heart known as Patent Foramen Ovale (PFO), which affects people globally.Approximately 27% of the population. This disease, under certain circumstancesCan lead to serious clinical symptoms such as migraines, ischemic stroke, and myocardial infarction.Huang explained: "During the fetal period, there is a channel in the heart called the foramen ovale. Normally, this channel closes within a few months after birth. However, in 27% of the population, this channel fails to close completely, which can impact health later on."

Traditional treatment methods for PFO include medication and surgery, but these approaches come with significant trauma, numerous complications, and long recovery times. Mr. Huang pointed out, "Although previous medication and surgical treatments have been effective, they bring about many complications and long-term suffering for patients, which has driven us to seek better solutions."

# Product Development and Innovation

In order to address these challenges,Conmind has developed aBrand-New Transcatheter Interventional Treatment Technology, aiming to achieve a residue-free and implant-free therapeutic effect.Huang, the general manager, provided a detailed introduction to the development process of this innovative product: "Our goal is to achieve an innovative product and surgical procedure through the use of newer materials and structural design."Effectively close the PFO without altering the cardiac anatomy,Thereby reducing postoperative complications and shortening recovery time.。”

Huang mentioned in particular that this innovative product has received strong support and cooperation from the president of Fu'an Hospital. The president proposed the concept of "Comprehensive Practice of Transcatheter Surgical Procedures," achieved through new materials and structural designs.Achieve the goal of intervention without residue or implantsHuang, the CEO, stated: "The design of this product took over three years. We verified its feasibility and safety through computer simulation and numerous animal experiments."

# Clinical Validation and Future Prospects

Huang, the CEO, provided a detailed introduction of the product's clinical validation process in his speech.Including multiple stages such as product design, simulation experiments, and animal experiments.He pointed out, "We have conducted more than 30 animal experiments to verify the feasibility of this product. All experiments were performed under ultrasound guidance to ensure the safety and effectiveness of the entire surgical procedure."

Recently, this innovative device completed the world's first implant surgery globally. The entire procedure was performed under ultrasound guidance without the use of radiation, fully verifying the safety and effectiveness of the device. Excitedly, Huang said, "We have successfully completed...The first implant surgery of this system in China was completed entirely under ultrasound guidance without the use of radiation, and the patient's recovery has been excellent.”

In addition, General Manager Huang also mentioned,This medical device has achieved full localization of its entire supply chain in China, eliminating any "bottleneck" issues. "All materials and components have been localized in China, which not only reduces costs but also ensures the stability of the supply chain."," Huang added. "We plan to initiate product registration between 2026 and 2027, with the goal of providing this innovative treatment solution to more patients in the future."

# Intellectual Property Protection

In his speech, Huang emphasized the importance of intellectual property protection. He pointed out,For this innovative device, Conmind has applied for 16 invention patents, two of which have been granted, and has laid out two international patents.Huang emphasized: "Through the protection of intellectual property rights, we can ensure that the company's rights and interests in production and R&D are not infringed."

Huang also mentioned that through the layout of intellectual property, CONMIND MEDICAL not only protected its own innovative achievements but also laid a solid foundation for future research and development and market expansion. He stated, "We will continue to increase our investment in intellectual property to ensure that our innovative achievements are effectively protected."

# The Path of Medical Innovation for Building the Future

Mr. Huang's speech showcased Conmind's outstanding achievements in device innovation and its firm confidence in future development. Through continuous technological innovation and clinical validation, Conmind will continue to provide safe and effective medical solutions for patients and healthcare providers worldwide, driving the advancement of medical technology.

Huang, the CEO, concluded: "Conmind will always adhere to the clinical needs as the guiding principle. Through continuous technological innovation and rigorous clinical validation, we aim to provide better medical devices and treatment solutions for patients and healthcare providers worldwide. We believe that, in the near future, Conmind's products will be widely used globally, benefiting more patients."

Mr. Huang's speech not only showcased Conmind's innovation capabilities and technical strength in the medical device field but also provided new ideas and directions for the development of the entire healthcare industry.

Editor-in-Chief | Zhao Qing Reviewed by | Yi He